- Liquid nitrogen- (LN2) based ProSense® found
to have favorable safety compared to argon-based cryoablation
systems, as well as being more cost effective and easier to
manage
- Independent study conducted at the European Institute of
Oncology (IEO) demonstrates interventional radiology use cases for
ProSense® for indications that are approved in various markets
across the world
CAESAREA, Israel, Sept. 16,
2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced the publication of an independent study led by Dr.
Franco Orsi, Director of
Interventional Radiology at the European Institute of Oncology
(IEO) in Milan, Italy and an
expert ProSense® user. The study titled "Liquid Nitrogen-Based
Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue
Tumors" was published by Oxford
University Press on behalf of the British Institute of
Radiology.
"Cryoablation with liquid nitrogen has a growing role in early
oncology treatments across a wide variety of cancer types and
particularly for patients who may have multiple comorbidities
and/or who want to avoid surgery. As interventional radiologists
are increasingly and effectively using cryoablation, it's important
to note Dr. Orsi and his colleagues underscore in the paper that
interventional radiology is now the fourth pillar of the oncology
field, alongside clinical oncology, surgical oncology and radiation
therapy," stated IceCure's Chief Executive Officer, Eyal Shamir. "We are very pleased that ProSense®
is providing a minimally invasive option to treat cancer patients
early, safely and effectively."
The study assessed the complication rate both during and 24
hours after treatment with IceCure's cryoablation system in 85
patients who were treated for 96 lesions (tumors), 36.4% of which
were lesions in bones, 18.8% in lungs, and 44.8% in soft tissue.
The primary technical success rate, defined as complete tumor
coverage, was 97.7% (83 of 85 patients). Patients with benign and
malignant tumors were treated for either curative or palliative
intent. Minor complications resolved themselves without
intervention or merely required simple interventions such as
drainage. The study concluded that cryoablation using an
LN2-based system, such as ProSense®, is safe across
various tumor sizes and locations, with only minor complications
observed.
LN2-based cryoablation was compared to argon-based
systems in the study who point to the benefits of LN2
procedures including its suitability for office-based procedures
performed under local anesthesia, compared to argon systems which
typically require general anesthesia and are therefore less
suitable for office procedures. The study also addresses the
challenges of argon systems requiring large argon gas cylinders,
which necessitate dedicated storage space and trained personnel for
transport, as well as the higher cost of the procedure due to the
use of multiple cryoprobes as well as the use of noble gases, argon
and helium. The study demonstrates that LN2-based systems, such as
ProSense®, are more cost effective and easier to manage.
Two previously published independent lung cancer studies of
ProSense® in the treatment of lung cancer, which evaluated the
procedure's local control and recurrence free rate, reported 96%
and 100% three-year recurrence free rates. Independent and
IceCure-sponsored studies of other interventional radiology
indications are ongoing.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced
liquid-nitrogen-based cryoablation therapy systems for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The Company's flagship ProSense® system
is marketed and sold worldwide for the indications cleared and
approved to date including in the U.S., Europe and China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statements in this press release when it discusses the
growing role of liquid nitrogen-based cryoablation in early
oncology treatments. Historical results of scientific research and
clinical and preclinical trials do not guarantee that the
conclusions of future research or trials will suggest identical or
even similar conclusions. Important factors that could cause actual
results, developments and business decisions to differ materially
from those anticipated in these forward-looking statements include,
among others: the Company's planned level of revenues and capital
expenditures; the Company's available cash and its ability to
obtain additional funding; the Company's ability to market and sell
its products; legal and regulatory developments in the United States and other countries; the
Company's ability to maintain its relationships with suppliers,
distributors and other partners; the Company's ability to maintain
or protect the validity of its patents and other intellectual
property; the Company's ability to expose and educate medical
professionals about its products; political, economic and military
instability in the Middle East,
specifically in Israel; as well as
those factors set forth in the Risk Factors section of the
Company's Annual Report on Form 20-F for the year ended
December 31, 2023 filed with the SEC
on April 3, 2024, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/study-published-in-the-british-journal-of-radiology-demonstrates-icecures-prosense-is-a-safe-procedure-with-97-7-technical-success-rate-in-treating-tumors-of-the-lung-bone-and-soft-tissues-302248877.html
SOURCE IceCure Medical